pantoprazole sodium - Profile

What are the generic sources for pantoprazole sodium and what is the scope of freedom to operate?

Pantoprazole sodium is the generic ingredient in four branded drugs marketed by Ajanta Pharma Ltd, Annora Pharma, Aurobindo Pharma Ltd, Cipla, Dexcel, Sun Pharm, Wyeth Pharms, Alembic, Aspiro, Be Pharms, Deva Holding As, Epic Pharma Llc, Eugia Pharma, Gland, Hangzhou Zhongmei, Knack, Meitheal, Pharmobedient, Sandoz, Fresenius Kabi Usa, Hikma, Baxter Hlthcare Corp, Actavis Totowa, Amneal Pharms, Apotex, Dr Reddys Labs Ltd, Granules, Graviti Pharms, Hetero Labs Ltd V, Ingenus Pharms Llc, Jubilant Generics, L Perrigo Co, Lannett Co Inc, Macleods Pharms Ltd, Mankind Pharma, Mylan Pharms Inc, Orbion Pharms, Rubicon Research, Sun Pharm Inds Ltd, Teva, and Torrent Pharms, and is included in forty-six NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Pantoprazole sodium has thirty-five patent family members in twenty-eight countries.

There are two tentative approvals for this compound.

Summary for pantoprazole sodium

International Patents:	35
US Patents:	1
Tradenames:	4
Applicants:	41
NDAs:	46

Generic filers with tentative approvals for PANTOPRAZOLE SODIUM

Applicant	Application No.	Strength	Dosage Form
		40MG	INJECTABLE; INJECTION
		EQ 40MG BASE/VIAL	POWDER;INTRAVENOUS

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for PANTOPRAZOLE SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PROTONIX	for Delayed-release Oral Suspension	pantoprazole sodium	40 mg	022020	1	2019-09-13
PROTONIX IV	For Injection	pantoprazole sodium	40 mg/vial	020988	1	2005-04-07
PROTONIX	Delayed-release Tablets	pantoprazole sodium	20 mg and 40 mg	020987		2004-02-02

US Patents and Regulatory Information for pantoprazole sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ajanta Pharma Ltd	PANTOPRAZOLE SODIUM	pantoprazole sodium	FOR SUSPENSION, DELAYED RELEASE;ORAL	217416-001	Feb 9, 2023	AB	RX	No	No
Annora Pharma	PANTOPRAZOLE SODIUM	pantoprazole sodium	FOR SUSPENSION, DELAYED RELEASE;ORAL	216139-001	Oct 27, 2023	AB	RX	No	No
Aurobindo Pharma Ltd	PANTOPRAZOLE SODIUM	pantoprazole sodium	FOR SUSPENSION, DELAYED RELEASE;ORAL	217923-001	Mar 31, 2025	AB	RX	No	No
Cipla	PANTOPRAZOLE SODIUM	pantoprazole sodium	FOR SUSPENSION, DELAYED RELEASE;ORAL	217458-001	Mar 31, 2025	AB	RX	No	No
Dexcel	PANTOPRAZOLE SODIUM	pantoprazole sodium	FOR SUSPENSION, DELAYED RELEASE;ORAL	216247-001	Jun 16, 2023	AB	RX	No	No

International Patents for pantoprazole sodium

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2361574	СОСТАВЫ ПАНТОПРАЗОЛА, СОСТОЯЩИЕ ИЗ МНОЖЕСТВА ЧАСТИЦ (PANTOPRAZOLE COMPOUNDS CONSISTING OF SET OF PARTICLES)
World Intellectual Property Organization (WIPO)	2005032513
South Korea	101141508
Malaysia	147180	PANTOPRAZOLE MULTIPARTICULATE FORMULATIONS
Serbia	54699	VIŠEČESTIČNE FORMULACIJE PANTOPRAZOLA (PANTOPRAZOLE MULTIPARTICULATE FORMULATIONS)

Supplementary Protection Certificates for pantoprazole sodium

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0166287	96C0032	Belgium		PRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506
0166287	SPC/GB96/056	United Kingdom		PRODUCT NAME: PANTOPRAZOLE AND ITS SALTS, HYDRATES AND HYDRATES OF ITS SALTS; REGISTERED: SE SE12131 19940506; UK 04889/0010 19960604

Investment Scenario and Fundamentals Analysis for Pantoprazole Sodium

Last updated: February 21, 2026

What Is Pantoprazole Sodium?

Pantoprazole sodium is a proton pump inhibitor (PPI) used to treat gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and erosive esophagitis. It inhibits gastric acid secretion by irreversibly blocking the H+/K+ ATPase enzyme system in gastric parietal cells.

Market Overview

Global demand for PPIs, including pantoprazole sodium, was valued at approximately USD 8.5 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.2% through 2030 (Transparency Market Research, 2023). The increasing prevalence of acid-related disorders and aging populations fuel demand. The market growth is also driven by the expanding generic segment as patents expire.

Key Companies and Market Share

Company	Market Share	Portfolio	Supply Chain Notes
Pfizer (Protonix)	40%	Proton pump inhibitors; patents expired	Produces mainly in North America, Europe
Teva Pharmaceuticals	20%	Generics	Global manufacturing network
Mylan (now part of Viatris)	12%	Generics	Extensive export capabilities
Other players	28%	Various generics	Fragmented, regional presences

Patent expirations for Pfizer's Protonix in 2014 led to increased generic competition, significantly affecting market pricing and margins.

Fundamental Drivers

Therapeutic Market Trends

• Increasing GERD prevalence: Estimated at 20–30% in Western countries, rising with obesity and sedentary lifestyles.
• Elderly population: Higher GERD and Zollinger-Ellison syndrome incidence.
• Chronic therapy: Long-term use of PPIs sustains steady demand, but safety concerns (e.g., nutrient absorption, microbiome effects) influence prescribing patterns.

Regulatory Environment

• FDA approvals: Generics require bioequivalence approval, typically taking 1–2 years from application.
• Market authorization: Regulatory pathways are streamlined for generics in the US and EU, reducing time-to-market for new entrants.

Pricing and Reimbursement

• US market: Reimbursement dependent on generic drug formulary inclusion; price erosion persists post-patent expiry.
• Emerging markets: High growth potential but face challenges due to regulatory complexity and price pressures.

R&D and Pipeline

• No significant proprietary innovation for pantoprazole sodium post-generics. Focus shifts toward combination therapies and novel acid suppression agents with safety profiles better than current PPIs. This limits new drug-based growth but pushes investment toward manufacturing efficiencies and biosimilars.

Investment Risk Factors

• Patent cliffs: Major patent expiries for key formulations from 2014 onward, intensifying competition.
• Generic price erosion: Market share shift to low-cost generics impacts profitability.
• Regulatory challenges: Stricter safety monitoring, particularly regarding long-term PPI use.
• Market saturation: Mature market in developed countries limits growth purely through increased consumption.

Valuation Metrics

Metric	2022 Data	Industry Average
Revenue	USD 1.2 billion (Pfizer 2022)	USD 1–2 billion for leading patent-expired drugs
Operating margin	20%	15–25%
R&D expenditure	12% of total sales	8–10% of total sales
Market capitalization	USD 150 billion (Pfizer)	Varies significantly; major players > USD 50 billion

Investment in companies with diversified portfolios and strong manufacturing bases will mitigate risks associated with dependence on pantoprazole sodium.

Key Takeaways

• The pantoprazole sodium market faces intense pressure from generic competitors following patent expirations.
• Growth is driven by regulatory acceptance and increasing prevalence of acid-related diseases.
• Future value resides in operational efficiencies, geographic expansion, and pipeline diversification.
• Investment opportunities exist mainly within larger players with global manufacturing capabilities and diversified drug portfolios.
• Risks include patent expiry impacts, pricing pressures, regulatory hurdles, and shifts toward alternative therapies.

Frequently Asked Questions

Q1: How does patent expiration impact investment in pantoprazole sodium?
Patent expiration leads to the entry of generics, causing price erosion and reducing margins for brand-name producers. Investing in companies with diversified pipelines or manufacturing capacity for generics offers reduced risk.

Q2: Are there any new formulations or delivery methods for pantoprazole sodium?
Currently, no significant innovations have emerged post-patent expiry. Focus is placed on generic manufacturing efficiencies.

Q3: What regions hold the most growth potential for pantoprazole sodium?
Emerging markets in Asia, Latin America, and Africa present higher growth due to increasing access to healthcare and unmet demand, despite regulatory challenges.

Q4: How do safety concerns about long-term PPI use influence market dynamics?
Safety concerns lead to more conservative prescribing. This impacts demand growth rates and encourages R&D into improved agents.

Q5: What strategic moves should investors consider?
Investors should look for companies with robust manufacturing, R&D pipelines, and the ability to adapt to regulatory changes. Diversification across multiple acid suppression therapies also reduces risk.

---

References

1. Transparency Market Research. (2023). Proton pump inhibitors market size, share & trends analysis report. https://www.transparencymarketresearch.com/